Machine Learning and Structure-Based Virtual Screening for Reliability-Aware G Protein-Coupled Receptor Ligand Prioritization
Pharmaceuticals · 17.11.2026 · 19 (11) · 1829
DOI: 10.3390/ph19111829 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 17.11.2026. Verfasst von Sphamandla Mtambo und 3 weiteren Autor:innen. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Predictive performance is necessary but insufficient for G protein-coupled receptor (GPCR) ligand prioritization, where heterogeneous bioactivity data, analog-series overlap, receptor-state dependence, and polypharmacology can weaken high-scoring predictions.
Methods
We developed an auditable ligand- and structure-based workflow across five human GPCRs: DRD2, CB2, ADORA2A, OPRM1, and CCR5. ChEMBL Ki, IC50, and EC50 data were evaluated using scaffold-disjoint validation, external validation, Venn–Abers calibration, conformal prediction, applicability-domain analysis, explainability, and receptor-state-aware docking.
Results
Deployed classifiers achieved held-out ROC-AUC values of 0.876–0.929. Under stricter temporal validation, models developed exclusively on pre-cutoff data achieved ROC-AUC values of 0.617–0.894 on the same post-cutoff scaffold-held-out compounds, indicating optimism in the original temporal stress test arising from post-cutoff analog information. De-overlapped BindingDB validation was informative for ADORA2A (n = 134) and OPRM1 (n = 49), whereas smaller DRD2, CB2, and CCR5 strata were descriptive only. Venn–Abers provided validity-aware probability intervals, although calibration metrics did not improve uniformly. Classification error increased outside the applicability domain for all targets, while regression conformal coverage decreased. Morgan fingerprints dominated predictive discrimination, whereas physicochemical descriptors recurred more frequently among top SHAP features across targets. DrugBank screening yielded 92 high-confidence, dataset-novel predictions, with structure-based filtering reducing prioritization to three evidence-classified compounds across three targets.
Conclusions
Overall, the study presents a reliability-aware framework for evidence-qualified GPCR ligand prioritization rather than an experimentally confirmed candidate-discovery campaign. Prospective biochemical and functional validation, including potency and selectivity assessment where appropriate, is required before candidate-level conclusions can be established.
Zitieren
APA
Mtambo, S., Makhathini, S. S., Kumalo, H. M., & Ssemakalu, C. C. (2026). Machine Learning and Structure-Based Virtual Screening for Reliability-Aware G Protein-Coupled Receptor Ligand Prioritization. Pharmaceuticals, 19(11), 1829. https://doi.org/10.3390/ph19111829
Vancouver
Mtambo S, Makhathini SS, Kumalo HM, Ssemakalu CC. Machine Learning and Structure-Based Virtual Screening for Reliability-Aware G Protein-Coupled Receptor Ligand Prioritization. Pharmaceuticals. 2026;19(11):1829. doi:10.3390/ph19111829
BibTeX
@article{Mtambo2026,
author = {Mtambo, Sphamandla and Makhathini, Sifiso S. and Kumalo, Hezekiel M. and Ssemakalu, Cornelius Cano},
title = {Machine Learning and Structure-Based Virtual Screening for Reliability-Aware G Protein-Coupled Receptor Ligand Prioritization},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1829},
doi = {10.3390/ph19111829}
}
EUVIMED